GSK Takes Pay-As-You Go Approach In Aspen Branded Generics Deal
Executive Summary
GlaxoSmithKline's licensing deal with South Africa-based branded generics drug maker Aspen is illustrative of the company's approach to acquisitions under new CEO Andrew Witty
You may also be interested in...
GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.
GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.
Only Alli Remains After Glaxo’s OTC Transaction With Aspen
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.